Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.

NCT00339703 | Completed

• 1 other identifier: FWH20040210H
• Study Type: observational
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether serum resistin levels in asthmatics are elevated. We will recruit subjects from the allergy/immunology clinic with a prior diagnosis of moderate to severe persistent asthma in addition to subjects being seen for evaluation of drug allergies. Based on the inclusion and exclusion criteria below, subjects will be placed into a control and asthma group. Each subject will undergo one blood draw in the main lab at WHMC, and return a lavender top tube to the allergy/immunology clinic for the EIA resistin assay. The patient will then have a brief encounter with a physician to determine an up to date history of asthma symptoms prior to participating in the exhaled NO test. The entire subject encounter will take place with one clinic visit, and requires no follow up visits as part of the study. The greatest risk to each subject will be the blood draw, as the exhaled NO is a completely non-invasive test. Plasma from each subject will be stored in a -70° freezer for no more than one month. Samples will be analyzed for resistin levels using an EIA assay run monthly. Mean values from serum CRP, serum glucose, serum resistin, and exhaled NO will be compared using a students T-test.

Conditions

Asthma

Keywords

Resistin; Asthma; CRP; Diabetes; FIZZ

Study Arms (2)

Control

Subjects between the ages of 18 and 65 without a diagnosis of asthma or other inflammatory disease were enrolled from the patient population at Wilford Hall Medical Center. Subjects underwent a single blood draw and spirometer.

Mild to Moderate Asthma

Subjects between the ages of 18 and 65, who were previously diagnosed with moderate to severe persistent asthma as defined by the National Asthma Education and Prevention Program (NAEPP), were enrolled from the Allergy and Immunology clinic at Wilford Hall Medical Center. Subjects on inhaled corticosteroids or other controller medications were allowed in the study, but subjects on oral corticosteroids were excluded. Subjects underwent a single blood draw and spirometer.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients enrolled to Wilford Hall Medical Center meeting the above eligibility criteria.

You may not qualify if:

• Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.

Sponsors & Collaborators

• 59th Medical Wing: lead

Study Sites (1)

Wilford Hall Medical Center

San Antonio, Texas, 78236, United States

Location

MeSH Terms

Conditions

Asthma; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Jeff S LaRochelle, MD

  United States Air Force

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: FED
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Physician

Study Record Dates

• First Submitted: June 19, 2006
• First Posted: June 21, 2006
• Study Start: November 1, 2004
• Primary Completion: May 1, 2006
• Study Completion: May 1, 2006
• Last Updated: January 19, 2021

Record last verified: 2021-01

Locations

US (1)